Quantum BioPharma Ltd. was featured in CTV News' W5 program, which aired Part Three of an investigative series examining the company's allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and RBC. The episodes detail rising market-manipulation cases in Canada and highlight Quantum's call for accountability. This coverage brings significant attention to allegations that could have far-reaching implications for market integrity and investor protection in Canadian financial markets.
CEO Zeeshan Saeed reaffirmed the company's commitment to defending shareholders and advancing MS research through its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Co-Executive Chair Anthony Durkacz has offered up to USD $7 million for information leading to a final judgment or settlement in related litigation. This substantial reward offer underscores the seriousness of the allegations and the company's determination to pursue legal remedies.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of Lucid-MS, targeting the underlying mechanism of multiple sclerosis. The company's dual focus on both legal action against alleged market manipulation and advancing neurological treatments creates a complex narrative about corporate resilience in challenging circumstances.
The company also invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining ownership of 20.11% of the company as of March 31, 2025. The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses. This business structure demonstrates the company's strategic approach to monetizing its intellectual property while maintaining control over pharmaceutical applications.
Additional information about the company is available in its newsroom at https://ibn.fm/QNTM. The press release containing this information was disseminated through InvestorWire, a specialized communications platform that is one of 70+ brands within the Dynamic Brand Portfolio at IBN, providing wire-grade press release syndication and corporate communications solutions. Full terms of use and disclaimers are available on the InvestorWire website at https://www.InvestorWire.com/Disclaimer. The national television coverage of Quantum BioPharma's allegations represents a significant development in bringing attention to complex financial market issues that typically receive limited public scrutiny.
